- Partnership is first-of-its-kind for both Siemens Healthineers and iMedrix in Southeast Asia.
- Focuses on enabling access to early and timely detection of heart diseases and real-time cardiology consultations, in an affordable manner.
- Partnership will leverage benefits of digitalization and AI to simplify access to quality care for patients and healthcare professionals.
Siemens Healthineers and iMedrix entered into a strategic partnership to build a tele-cardiology network in Southeast Asia, to help analyse population health using AI and data analytics and further ease the burden of cardiovascular diseases (CVD) in the region. The partnership will utilise the expertise of iMedrix in mobile cardiology to acquire and analyse clinical grade ECGs and help identify high-risk patients. Siemens Healthineers vast installations of interventional cardiology solutions will further enable accurate diagnosis of these patients and help manage precise treatment planning.
CVD remains the leading cause of death and premature death globally. Among the 18.6 million CVD deaths worldwide in 2019, 58% occurred in Asia1. According to the World Health Organization, the time has come to implement feasible and affordable strategies for the prevention and control of CVD. The partnership between Siemens Healthineers and iMedrix is a tangible response to this need, where AI and data-driven insights can assist clinical decision-making and make healthcare accessible, affordable and available to all.
iMedrix’s flagship product KardioScreen™ is a US FDA-cleared, cloud-based solution that simplifies the acquisition and analysis of clinical grade ECG, in out-of-hospital settings. KardioScreen™ Telecardiology workflow connects the ‘point of care’ to a remote physician, allowing real-time consultation and advice within a matter of minutes. The cutting-edge mobility enables unskilled and non-medical staff to operate the device, offering higher efficiencies and significant throughput advantage over traditional ECG devices. This mobility feature also overcomes the challenge of non-availability of ECG tests and interpretation in remote areas, as traditionally, ECG devices are mostly available in hospitals and large diagnostic centres.
KardioScreen™ can accurately detect and diagnose major electrophysiological abnormalities with just the click of a button and is complimented by an AI-driven CVD risk assessment at 75% less cost than what is available today.
“At Siemens Healthineers our focus is to fight the most threatening diseases like Cardiovascular diseases. Our collaboration with iMedrix further strengthens this focus, where we together want to identify high-risk cardiac patients and provide early and planned treatment to them, especially in the remote areas. This first-of-its-kind collaboration will not only enable early diagnosis and treatment, but will also make quality healthcare accessible and affordable. With the tele-cardiology network, we would be able to generate deeper insights of population health in this region,” elaborates Subhadip Mukherjee, Head of Advanced Therapies, Southeast Asia, Siemens Healthineers.
“We are excited about our partnership with Siemens Healthineers and it cements our ambition to work toward the UN goal of a 25% reduction in CVD by 2025. This is done by early detection, diagnosis, and treatment of heart disease. KardioScreen™ is truly democratizing cardiac risk assessment and makes affordable, superior cardiac care available to everyone, anytime and anywhere. We look forward to working with Siemens Healthineers in Southeast Asia and driving the socialization of early detection of heart disease. We will expect to record a reduction in overall cost of care, based on early intervention and an increase in QALY*, especially in the undiagnosed and underserved population”, shares Ashvanni Srivastava, COO, iMedrix.
“Over the last four years, iMedrix has touched over 400,000 lives, curating one of the largest and most diverse ‘out-of-hospital’ cardiovascular disease databases enriched with clinical grade ECGs and other vital parameters. It has been granted a US patent for its tech advancement and innovative methodology, giving KardioScreen a significant edge over most available solutions, delivering medical-grade ECGs in real time, even in harsh operating conditions and without the intervention of skilled operators” says Srikanth Jadcherla, Founder, iMedrix.
About Siemens Healthineers
Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) pioneers breakthroughs in healthcare. For everyone. Everywhere. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers and its regional companies is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care. In fiscal 2021, which ended on September 30, 2021, Siemens Healthineers, which has approximately 66,000 employees worldwide, generated revenue of €18.0 billion and adjusted EBIT of €3.1 billion. For more information, please visit: www.siemens-healthineers.com.
iMedrix is a cutting edge MedTech company with focus to transform early detection and care for Cardiovascular disease. HQ in California, USA, iMedrix is a leader in Mobile Cardiology with deployments in India and multiple countries across SE Asia, Africa and Middle East. iMedrix flagship innovation KardioScreen ™ is the leading medical grade mobile-connected solution with US FDA 510 (k) clearance, the gold standard of clinical grade efficacy, quality and safety. iMedrix is partner of choice on "Access to Care" programs for global Medtech leaders and health agencies, leading hospitals, healthcare providers and public health in SE Asia, Middle-east and Africa. With over 400,000 lives touched across 14 countries, and a goal to reach 10M lives in a couple of years, iMedrix is truly bringing Diversity, Equity and Inclusion in Cardiac Risk Assessment & Care. www.imedrix.com
Mr. Kyle Dacosta
Phone: +65 9863 2203
Phone: +91 99649 99977